MX2021015528A - Exosomas para el tratamiento de enfermedades. - Google Patents
Exosomas para el tratamiento de enfermedades.Info
- Publication number
- MX2021015528A MX2021015528A MX2021015528A MX2021015528A MX2021015528A MX 2021015528 A MX2021015528 A MX 2021015528A MX 2021015528 A MX2021015528 A MX 2021015528A MX 2021015528 A MX2021015528 A MX 2021015528A MX 2021015528 A MX2021015528 A MX 2021015528A
- Authority
- MX
- Mexico
- Prior art keywords
- exosomes
- diseases
- disorders
- population
- conditions
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 7
- 201000010099 disease Diseases 0.000 title abstract 4
- 210000001808 exosome Anatomy 0.000 title abstract 4
- -1 CD11c Proteins 0.000 abstract 4
- 208000035475 disorder Diseases 0.000 abstract 3
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 abstract 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 abstract 1
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 abstract 1
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 abstract 1
- 101150013553 CD40 gene Proteins 0.000 abstract 1
- 102100032912 CD44 antigen Human genes 0.000 abstract 1
- 102100025222 CD63 antigen Human genes 0.000 abstract 1
- 102100027221 CD81 antigen Human genes 0.000 abstract 1
- 102100037904 CD9 antigen Human genes 0.000 abstract 1
- 102100025137 Early activation antigen CD69 Human genes 0.000 abstract 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 abstract 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 abstract 1
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 abstract 1
- 101000934368 Homo sapiens CD63 antigen Proteins 0.000 abstract 1
- 101000914479 Homo sapiens CD81 antigen Proteins 0.000 abstract 1
- 101000738354 Homo sapiens CD9 antigen Proteins 0.000 abstract 1
- 101000916489 Homo sapiens Chondroitin sulfate proteoglycan 4 Proteins 0.000 abstract 1
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 abstract 1
- 101001103039 Homo sapiens Inactive tyrosine-protein kinase transmembrane receptor ROR1 Proteins 0.000 abstract 1
- 101000994369 Homo sapiens Integrin alpha-5 Proteins 0.000 abstract 1
- 101000935043 Homo sapiens Integrin beta-1 Proteins 0.000 abstract 1
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 abstract 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 abstract 1
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 abstract 1
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 abstract 1
- 101001103036 Homo sapiens Nuclear receptor ROR-alpha Proteins 0.000 abstract 1
- 101000622137 Homo sapiens P-selectin Proteins 0.000 abstract 1
- 101000829725 Homo sapiens Phospholipid hydroperoxide glutathione peroxidase Proteins 0.000 abstract 1
- 101001071312 Homo sapiens Platelet glycoprotein IX Proteins 0.000 abstract 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 abstract 1
- 101000884271 Homo sapiens Signal transducer CD24 Proteins 0.000 abstract 1
- 101001056234 Homo sapiens Sperm mitochondrial-associated cysteine-rich protein Proteins 0.000 abstract 1
- 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 abstract 1
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 abstract 1
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 abstract 1
- 102100039615 Inactive tyrosine-protein kinase transmembrane receptor ROR1 Human genes 0.000 abstract 1
- 102100032817 Integrin alpha-5 Human genes 0.000 abstract 1
- 102100022297 Integrin alpha-X Human genes 0.000 abstract 1
- 102100025304 Integrin beta-1 Human genes 0.000 abstract 1
- 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 abstract 1
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 abstract 1
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 abstract 1
- 102100023472 P-selectin Human genes 0.000 abstract 1
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 abstract 1
- 102100036851 Platelet glycoprotein IX Human genes 0.000 abstract 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 abstract 1
- 102100038081 Signal transducer CD24 Human genes 0.000 abstract 1
- 102100026503 Sperm mitochondrial-associated cysteine-rich protein Human genes 0.000 abstract 1
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 abstract 1
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 abstract 1
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 abstract 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 abstract 1
- 230000032683 aging Effects 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 230000002526 effect on cardiovascular system Effects 0.000 abstract 1
- 230000002496 gastric effect Effects 0.000 abstract 1
- 210000003734 kidney Anatomy 0.000 abstract 1
- 210000004185 liver Anatomy 0.000 abstract 1
- 210000004072 lung Anatomy 0.000 abstract 1
- 210000000952 spleen Anatomy 0.000 abstract 1
- 230000009885 systemic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0605—Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
- C12N2310/141—MicroRNAs, miRNAs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Developmental Biology & Embryology (AREA)
- Cell Biology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Reproductive Health (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Pregnancy & Childbirth (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Plant Pathology (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962863767P | 2019-06-19 | 2019-06-19 | |
| US201962891700P | 2019-08-26 | 2019-08-26 | |
| US201962905117P | 2019-09-24 | 2019-09-24 | |
| US201962924147P | 2019-10-21 | 2019-10-21 | |
| PCT/US2020/038828 WO2020257720A1 (en) | 2019-06-19 | 2020-06-19 | Exosomes for disease treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021015528A true MX2021015528A (es) | 2022-02-03 |
Family
ID=71662298
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021015528A MX2021015528A (es) | 2019-06-19 | 2020-06-19 | Exosomas para el tratamiento de enfermedades. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20230181649A1 (https=) |
| EP (1) | EP3986381A1 (https=) |
| JP (1) | JP2022538004A (https=) |
| KR (1) | KR20220024060A (https=) |
| CN (1) | CN114302731A (https=) |
| AU (1) | AU2020298316A1 (https=) |
| BR (1) | BR112021025512A2 (https=) |
| CA (1) | CA3142020A1 (https=) |
| IL (1) | IL288958A (https=) |
| MX (1) | MX2021015528A (https=) |
| PH (1) | PH12021553167A1 (https=) |
| WO (1) | WO2020257720A1 (https=) |
| ZA (1) | ZA202109828B (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3801028A4 (en) | 2018-05-30 | 2022-04-13 | Direct Biologics LLC | A growth factor and extracellular vesicle frozen or powdered additive comprising a mesenchymal stem cell (msc) preparation and methods of use |
| US12569517B2 (en) | 2019-02-07 | 2026-03-10 | Direct Biologics, Llc | Method for treating osteoarthritis with mesenchymal stem cell exosomes |
| US12213995B2 (en) | 2019-07-18 | 2025-02-04 | Direct Biologics, Llc | Preparations comprising mesenchymal stem cells and cannabinoids and methods of their use |
| US20210322483A1 (en) | 2020-04-16 | 2021-10-21 | Ichilov Tech Ltd. | Cell-derived particles presenting heterologous cd24 and use thereof in therapy |
| US20210324339A1 (en) | 2020-04-16 | 2021-10-21 | Ichilov Tech Ltd. | Cell-derived particles presenting heterologous cd24 and use thereof in therapy |
| KR20230004709A (ko) | 2020-04-22 | 2023-01-06 | 다이렉트 바이오로직스 엘엘씨 | 감염성 질환과 연관된 염증성 병태를 치료하기 위한 방법 및 조성물 |
| KR102317052B1 (ko) * | 2020-05-04 | 2021-10-25 | 주식회사 티에스셀바이오 | 태반 유래의 세포외 소포의 항염증 항바이러스 효과 조성물 |
| WO2022154149A1 (ko) * | 2021-01-14 | 2022-07-21 | (주)엑솔런스 | 세포외소포체를 이용한 백신 조성물 |
| WO2022183047A1 (en) * | 2021-02-26 | 2022-09-01 | The Methodist Hospital | Regulatory t cell (treg) extracellular vesicle compositions and methods |
| CN113171379A (zh) * | 2021-04-28 | 2021-07-27 | 奥启(深圳)创投科技有限公司 | 一种间充质干细胞外泌体在制备脂肪性肝病药物中的应用 |
| CN114085817B (zh) * | 2021-11-26 | 2025-04-15 | 三代康年(上海)医疗科技有限公司 | 一种包载microRNA的外泌体的制备方法及其产品和应用 |
| CN119013038A (zh) * | 2022-04-08 | 2024-11-22 | 创新外科再生控股有限公司 | 用于伤口愈合和促进毛发生长和/或再生的nampt |
| CN117414415B (zh) * | 2023-07-10 | 2024-10-18 | 中山大学·深圳 | 蛋白质精氨酸甲基转移酶7在促进毛发生长中的应用 |
| WO2025048567A1 (ko) * | 2023-08-31 | 2025-03-06 | 의료법인 성광의료재단 | 인간 태반 유래 중간엽 줄기 세포에서 분리된 엑소좀을 포함하는 시신경 질환 및 미토콘드리아 기능이상 질환 예방 또는 치료용 약학적 조성물 |
| KR20250139693A (ko) * | 2024-03-15 | 2025-09-23 | 가톨릭대학교 산학협력단 | Ssea3 및 cd105를 발현하는 신경능 유래 코 줄기세포 유효성분으로 포함하는 알츠하이머병 예방 또는 치료용 약학적 조성물 |
| US12502407B2 (en) | 2024-04-25 | 2025-12-23 | Direct Biologics, Llc | Treatment of fistula with bone marrow mesenchymal stem cell derived extracellular vesicles |
| CN120437174A (zh) * | 2025-02-28 | 2025-08-08 | 单核细胞治疗有限公司 | 脐带血外泌体在制备治疗衰老引发的眼科疾病的药物中的应用 |
| CN120927522B (zh) * | 2025-10-14 | 2026-02-03 | 亿航(苏州)生物医药有限公司 | 辅助诊断或鉴别血管性认知障碍的标志物、试剂盒及用途 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1969147B1 (en) * | 2006-01-05 | 2014-07-30 | The Ohio State University Research Foundation | microRNA-based methods for the diagnosis of stomach cancer |
| EP3115469B1 (en) * | 2007-11-19 | 2020-04-29 | Celera Corporation | Lung cancer markers and uses thereof |
| CN102307475A (zh) * | 2009-02-04 | 2012-01-04 | 彼帕科学公司 | 用与生长因子抑制剂组合的parp抑制剂治疗肺癌 |
| WO2016057755A1 (en) * | 2014-10-09 | 2016-04-14 | Anthrogenesis Corporation | Placenta-derived adherent cell exosomes and uses thereof |
| MX2017015147A (es) * | 2015-05-26 | 2018-03-28 | Celularity Inc | Angiogenesis usando celulas madre de placenta estimuladas. |
| CN105861430B (zh) * | 2016-04-29 | 2019-07-23 | 南京大学 | 一种外泌体、外泌体的制备方法及其在制备治疗脓毒症药物或者制剂中的应用 |
| KR20190109389A (ko) * | 2016-11-03 | 2019-09-25 | 엑소스템 바이오텍 리미티드 | 간엽 줄기 세포 집단, 이들의 산물 및 이들의 용도 |
| MX2020005100A (es) * | 2017-11-16 | 2020-11-24 | Celularity Inc | Cultivo de placenta para aislar exosomas. |
-
2020
- 2020-06-19 CA CA3142020A patent/CA3142020A1/en active Pending
- 2020-06-19 US US17/596,827 patent/US20230181649A1/en active Pending
- 2020-06-19 CN CN202080042501.XA patent/CN114302731A/zh active Pending
- 2020-06-19 KR KR1020217041154A patent/KR20220024060A/ko not_active Ceased
- 2020-06-19 AU AU2020298316A patent/AU2020298316A1/en not_active Abandoned
- 2020-06-19 WO PCT/US2020/038828 patent/WO2020257720A1/en not_active Ceased
- 2020-06-19 PH PH1/2021/553167A patent/PH12021553167A1/en unknown
- 2020-06-19 BR BR112021025512A patent/BR112021025512A2/pt not_active IP Right Cessation
- 2020-06-19 JP JP2021575247A patent/JP2022538004A/ja active Pending
- 2020-06-19 MX MX2021015528A patent/MX2021015528A/es unknown
- 2020-06-19 EP EP20742527.3A patent/EP3986381A1/en not_active Withdrawn
-
2021
- 2021-12-01 ZA ZA2021/09828A patent/ZA202109828B/en unknown
- 2021-12-13 IL IL288958A patent/IL288958A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ZA202109828B (en) | 2024-04-24 |
| KR20220024060A (ko) | 2022-03-03 |
| WO2020257720A1 (en) | 2020-12-24 |
| BR112021025512A2 (pt) | 2022-02-01 |
| CN114302731A (zh) | 2022-04-08 |
| US20230181649A1 (en) | 2023-06-15 |
| EP3986381A1 (en) | 2022-04-27 |
| JP2022538004A (ja) | 2022-08-31 |
| IL288958A (en) | 2022-02-01 |
| AU2020298316A1 (en) | 2021-12-16 |
| CA3142020A1 (en) | 2020-12-24 |
| PH12021553167A1 (en) | 2022-08-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021015528A (es) | Exosomas para el tratamiento de enfermedades. | |
| SA519400950B1 (ar) | Masp-3 تركيبات وطرق لتثبيط لعلاج أمراض واضطرابات مختلفة | |
| MX2022004082A (es) | Anticuerpos biespecificos contra cd3 y cd20. | |
| MX2018009824A (es) | Composiciones para el cuidado personal. | |
| ZA202001057B (en) | Inhibiting ubiquitin specific peptidase 30 | |
| PH12020551427A1 (en) | Epinephrine spray formulations | |
| EP3735976A3 (en) | Therapeutic use of mitochondria and combined mitochondrial agents | |
| NZ744307A (en) | Treatment of fibrosis | |
| MX2017013591A (es) | Regimen para el cuidado del cabello que usa un acondicionador concentrado de espuma en aerosol. | |
| MX2017013583A (es) | Regimen de cuidado del cabello mediante el uso de un acondicionador concentrado de espuma mecanica. | |
| MY197631A (en) | Formulations of (r)-2-amino-3-phenylpropyl carbamate | |
| MX2017003966A (es) | Composiciones de tratamiento y/o limpieza que comprenden composiciones para reducir el mal olor. | |
| MX2023005484A (es) | Analogos de carbamoil fenilalaninol y usos de los mismos. | |
| PH12019500751A1 (en) | Carbamoyl phenylalaninol compounds and uses thereof | |
| SA519410324B1 (ar) | صياغات رش إيبينيفرين | |
| MX2023010501A (es) | Profarmacos de dantroleno y metodos de su uso. | |
| MX2019011697A (es) | Agentes para aumentar la secrecion de lipidos en la glandula de meibomio. | |
| CL2017000475A1 (es) | Composición para formulación cosmética que consiste en una mezcla de hasta 3 componentes seleccionados de manteca de murumuru, manteca de ucuuba, aceite de nuez de brasil, aceite de maracuyá, manteca de copoazú, aceite de acai y aceite de andiroba y/o ésteres de los mismos; producto cosmético. | |
| MX2017007633A (es) | Limpiador liquido para la piel. | |
| MX2018016091A (es) | Composiciones de fosfolipidos. | |
| CL2017000118A1 (es) | Métodos y composiciones para tratar desórdenes relacionados con el vih | |
| CL2021000660A1 (es) | Compuestos quelantes de hierro para tratar condiciones estéticas de la piel | |
| MY188028A (en) | Sialylated glycoprotein compositions and uses thereof | |
| MX2021008188A (es) | Compuestos de anandamida. | |
| MY188694A (en) | Anticariogenic agent and anticariogenic composition |